AI + Bio Scientist | Company Builder | CTO (LABI) at Luma Group I build intelligence layers for biotech decisions. At Luma Group, I’m spearheading LABI, an end-to-end AI-powered investing platform that fuses best-in-class LLMs with graph-native AI so investors, operators, and scientists can reason across messy biological data (patients, pathways, trials) with insights that are traceable, transparent, and grounded in biology. Previously, I co-founded and led OneThree Biotech, where we used AI to identify novel oncology targets and partnered with biopharma; I also served as Interim CPO at Lantern Pharma (RADR) and Senior Director, AI Product at RAVen (RA Ventures). My throughline: turning fragmented datasets into rigorous, decision-grade products. across discovery, clinical development, and diligence. If it involves building AI that actually understands biology (and proving it with outcomes, not hype) I’m in. What I Offer on Hubble ✅ AI strategy for biotech (LLMs + graph AI) ✅ Technical & product due diligence for techbio/AI startups ✅ Integrating AI into Venture Funds/Investing ✅ Target/asset triage & portfolio decision support ✅ Go-to-market for AI platforms in biotech & life sciences ✅ Team design: hiring/playbooks for AI x Bio product, DS, and comp bio Background & Highlights ✅ CTO (LABI), Luma Group – building a graph-native, evidence-citing AI platform for biotech intelligence ✅ CEO & Co-Founder, OneThree Biotech – raised ~$10M; led ATLANTIS platform; advanced 4 novel oncology targets to preclinical PoC; closed partnerships totaling $50M+ downstream value ✅ Interim CPO, Lantern Pharma (RADR) – deployed AI for trial data ingestion, biomarker identification, inclusion criteria; built ADC target-payload design pipeline ✅ Senior Director, AI Product, RAVen – product strategy at the intersection of FHIR, clinical workflows, and AI ✅ Advisor/Venture Consultant – technical diligence (algorithms, code, data), KOL synthesis, competitive landscapes ✅ PhD, Computational Biology & Medicine, Weill Cornell; BS, Biochemistry & Molecular Biology, UT Knoxville (Summa Cum Laude, Phi Beta Kappa) Whether you’re evaluating an asset, building a biologically-faithful AI product, or pressure-testing a platform before scale—let’s connect.